|
Online Database of Chemicals from Around the World | Search | Submit | Advertise | |
Home >> Chemical Listing >> BMS-641988>> Market Analysis Reports |
Market Analysis Reports of BMS-641988 |
|
Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in The Treatment Paradigm of Prostate Cancer XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting?Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry In recent past approval and launch of various newer treatment ... Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a bigger pie in Prostate cancer & Finding its niche in crowded BC market Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the race? Rising star Anti Androgens – Third generation ... |